Immunogenicity of human neuroblastoma - PubMed (original) (raw)
Review
Immunogenicity of human neuroblastoma
Ignazia Prigione et al. Ann N Y Acad Sci. 2004 Dec.
Abstract
Neuroblastoma (NB) is a neuroectodermal tumor that affects children in the first years of life. Half of NB cases present with metastatic disease at diagnosis and have a poor prognosis, in spite of the most advanced chemotherapeutic protocols combined with autologous hematopoietic stem cell transplantation. Among the new avenues for NB treatment that are being explored, immunotherapy has attracted much interest. Emphasis has been placed on monoclonal antibodies directed to tumor-associated antigens--in particular the disialoganglioside GD2--that have been tested in the clinical setting with promising results. In addition, stimulation of cell-mediated antitumor effector mechanisms have been attempted-for example, by recombinant interleukin (IL)-2 administration. Nonetheless, the issue of the immunogenicity of human NB cells has never been thoroughly addressed. Here we shall review the work carried out in our lab in recent years and show that NB cells express tumor-associated antigens, such as MAGE-3, but lack constitutive expression of costimulatory molecules and surface HLA class I and II molecules. As such, NB cells are likely to be ignored by the host T cell compartment, since expression of HLA and costimulatory molecules on antigen presenting cells are sine qua non conditions for efficient peptide presentation to T cells and for the subsequent activation and clonal expansion of the latter cells. Notably, in vitro experiments with NB cell lines demonstrated that surface HLA class I molecules and the CD40 costimulatory molecule were upregulated following cell incubation with recombinant interferon-gamma. Interaction of CD40 with recombinant CD40 ligand induced apoptosis of NB cells through a caspase 8-dependent mechanism. Collectively, these results indicate that the immunogenicity of human NB cells is very low but suggest that manipulation by cytokine administration or gene transfer can increase their immunogenic potential. On the other hand, NB cells represent an excellent target for natural killer cells, the potential role of which in immunotherapy of NB is now being investigated.
Similar articles
- The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A, Gil M, Horwacik I, Odrowaz Z, Kozbor D, Rokita H. Kowalczyk A, et al. Cancer Lett. 2009 Aug 28;281(2):171-82. doi: 10.1016/j.canlet.2009.02.040. Epub 2009 Mar 31. Cancer Lett. 2009. PMID: 19339105 - Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G. Koido S, et al. Clin Cancer Res. 2005 Nov 1;11(21):7891-900. doi: 10.1158/1078-0432.CCR-05-1330. Clin Cancer Res. 2005. PMID: 16278414 - Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma.
Jarnjak-Jankovic S, Pettersen RD, Saebøe-Larssen S, Wesenberg F, Olafsen MR, Gaudernack G. Jarnjak-Jankovic S, et al. Cancer Gene Ther. 2005 Aug;12(8):699-707. doi: 10.1038/sj.cgt.7700820. Cancer Gene Ther. 2005. PMID: 15846368 - [Rational bases for new approaches to the therapy of pediatric solid tumors: immunotherapy and gene therapy].
Pistoia V, Prigione I, Facchetti P, Corrias MV. Pistoia V, et al. Pediatr Med Chir. 1994 May-Jun;16(3):219-25. Pediatr Med Chir. 1994. PMID: 7971443 Review. Italian. - Prospects for CD40-directed experimental therapy of human cancer.
Tong AW, Stone MJ. Tong AW, et al. Cancer Gene Ther. 2003 Jan;10(1):1-13. doi: 10.1038/sj.cgt.7700527. Cancer Gene Ther. 2003. PMID: 12489023 Review.
Cited by
- Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma.
Mao C, Poimenidou M, Craig BT. Mao C, et al. Cancers (Basel). 2024 Aug 17;16(16):2865. doi: 10.3390/cancers16162865. Cancers (Basel). 2024. PMID: 39199637 Free PMC article. Review. - Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.
Zappa E, Vitali A, Anders K, Molenaar JJ, Wienke J, Künkele A. Zappa E, et al. Eur J Cancer. 2023 Nov;194:113347. doi: 10.1016/j.ejca.2023.113347. Epub 2023 Sep 18. Eur J Cancer. 2023. PMID: 37832507 Free PMC article. Review. - Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory.
El-Hajjar M, Gerhardt L, Hong MMY, Krishnamoorthy M, Figueredo R, Zheng X, Koropatnick J, Maleki Vareki S. El-Hajjar M, et al. Mol Ther. 2023 Feb 1;31(2):535-551. doi: 10.1016/j.ymthe.2022.08.025. Epub 2022 Sep 6. Mol Ther. 2023. PMID: 36068918 Free PMC article. - Tumor Microenvironment Profiling Identifies Prognostic Signatures and Suggests Immunotherapeutic Benefits in Neuroblastoma.
Feng C, Li T, Xiao J, Wang J, Meng X, Niu H, Jiang B, Huang L, Deng X, Yan X, Wu D, Fang Y, Lin Y, Chen F, Wu X, Zhao X, Feng J. Feng C, et al. Front Cell Dev Biol. 2022 Apr 14;10:814836. doi: 10.3389/fcell.2022.814836. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35493068 Free PMC article. - Signaling domains of cancer-associated glycolipids.
Furukawa K, Ohmi Y, Hamamura K, Kondo Y, Ohkawa Y, Kaneko K, Hashimoto N, Yesmin F, Bhuiyan RH, Tajima O, Furukawa K. Furukawa K, et al. Glycoconj J. 2022 Apr;39(2):145-155. doi: 10.1007/s10719-022-10051-1. Epub 2022 Mar 22. Glycoconj J. 2022. PMID: 35315508 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous